Jasper Ridge Partners L.P. held its position in Acceleron Pharma Inc. (NASDAQ:XLRN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,498 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Jasper Ridge Partners L.P.’s holdings in Acceleron Pharma were worth $380,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Teachers Advisors LLC lifted its position in Acceleron Pharma by 3.0% during the 4th quarter. Teachers Advisors LLC now owns 45,138 shares of the biopharmaceutical company’s stock worth $1,152,000 after buying an additional 1,296 shares in the last quarter. Bank of Montreal Can acquired a new position in Acceleron Pharma during the 1st quarter worth about $237,000. Nationwide Fund Advisors lifted its position in Acceleron Pharma by 10.5% during the 1st quarter. Nationwide Fund Advisors now owns 22,737 shares of the biopharmaceutical company’s stock worth $602,000 after buying an additional 2,168 shares in the last quarter. Russell Investments Group Ltd. lifted its position in Acceleron Pharma by 88.9% during the 1st quarter. Russell Investments Group Ltd. now owns 27,850 shares of the biopharmaceutical company’s stock worth $737,000 after buying an additional 13,108 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its position in Acceleron Pharma by 106.1% during the 1st quarter. Wells Fargo & Company MN now owns 79,462 shares of the biopharmaceutical company’s stock worth $2,104,000 after buying an additional 40,910 shares in the last quarter. Hedge funds and other institutional investors own 88.07% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/12/jasper-ridge-partners-l-p-has-380000-stake-in-acceleron-pharma-inc-xlrn.html.

Several research analysts recently issued reports on the stock. UBS AG reiterated a “buy” rating and set a $50.00 price target (up previously from $36.00) on shares of Acceleron Pharma in a research report on Tuesday. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Acceleron Pharma in a research report on Tuesday, September 5th. Cann reiterated a “hold” rating on shares of Acceleron Pharma in a research report on Tuesday, September 5th. ValuEngine upgraded shares of Acceleron Pharma from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Zacks Investment Research downgraded shares of Acceleron Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $42.21.

Shares of Acceleron Pharma Inc. (XLRN) traded up 1.62% during mid-day trading on Tuesday, hitting $38.38. The stock had a trading volume of 204,679 shares. The stock’s 50-day moving average is $34.79 and its 200-day moving average is $30.50. The firm’s market capitalization is $1.48 billion. Acceleron Pharma Inc. has a 1-year low of $23.07 and a 1-year high of $41.69.

Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.12). The company had revenue of $3.10 million during the quarter, compared to analyst estimates of $3.69 million. Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. Acceleron Pharma’s revenue was down 3.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.59) earnings per share. Equities analysts expect that Acceleron Pharma Inc. will post ($2.70) earnings per share for the current year.

In other Acceleron Pharma news, CFO Kevin F. Mclaughlin sold 34,400 shares of Acceleron Pharma stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $32.00, for a total value of $1,100,800.00. Following the completion of the sale, the chief financial officer now directly owns 80,950 shares in the company, valued at $2,590,400. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Ravindra Kumar sold 937 shares of Acceleron Pharma stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $32.00, for a total value of $29,984.00. Following the completion of the sale, the senior vice president now owns 96,264 shares of the company’s stock, valued at $3,080,448. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 64,402 shares of company stock worth $2,105,416. 3.90% of the stock is owned by insiders.

Acceleron Pharma Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Stock Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related stocks with our FREE daily email newsletter.